热门资讯> 正文

Kamada的血浆中心获得FDA批准，下一步目标是获得EMA批准

2026-03-26 19:43

Kamada Ltd(KMDA) 0

Kamada (KMDA), a biopharmaceutical company, announced that the FDA has approved its Kamada Plasma collection center in San Antonio, TX, following a February 2026 on-site inspection.
The San Antonio center can support 50 donor beds and, at full capacity, produce up to 50K liters annually.
It also plans to pursue EMA inspection and approval of its San Antonio facility following FDA clearance.
The center could make $8–$10M in annual revenues from normal source plasma at full capacity.

More on Kamada

Kamada's Pipeline And Biosimilars Set Stage For Future Earnings Expansion
Kamada Ltd. (KMDA) Q4 2025 Earnings Call Transcript
Kamada 2025/2026 Outlook: Evaluating Revenue Growth And Product Drivers
Kamada forecasts double-digit profitable growth in 2026
Seeking Alpha’s Quant Rating on Kamada

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。